Cerenovus Division

[anonymous]

Lots of new data on MMA embolization at the ISC meeting. Unfortunately MEMBRANE was not one of them.

 

[anonymous]

If I have to listen to this clown anymore at our ntl mtg- I’m going to be sick. He clearly has no idea what is going on and how to lead

 

[anonymous]

Last place in the market due to coming to market last with inferior products. Same as its always been here. Will never change.

 

[anonymous]

Last place in the market due to coming to market last with inferior products. Same as its always been here. Will never change.

yesterday's technology at tomorrow's prices

 

[anonymous]

Sacki, as we call him, has done nothing good for the place. Look around for crying out load!

 

[anonymous]

Cerenovus is on the block​

Johnson & Johnson aims to sell Cerenovus for over $1 billion - Financial Times By Investing.com

 

[anonymous]

Cerenovus is on the block​

Johnson & Johnson aims to sell Cerenovus for over $1 billion - Financial Times By Investing.com

Saki set to make a cool million in this sell off, laughing all the way to the bank.

 

[anonymous]

Better start bidding on new jobs, Irvine and Galway people.

 

[anonymous]

Saki set to make a cool million in this sell off, laughing all the way to the bank.

So will Saki move with the division or will JnJ retain him? Eventually JnJ Medtech will be stripped down to nothing and parted out.

 

[anonymous]

So will Saki move with the division or will JnJ retain him? Eventually JnJ Medtech will be stripped down to nothing and parted out.

Why will they? CSS is fastest growing business in MedTech.

 

[anonymous]

Why will they? CSS is fastest growing business in MedTech.

Not anymore. CSS was basically BWI. BWI is falling faster than a dress on prom night with their Varipulse catheter that causes strokes, and both Boston Scientific and Medtronic are gobbling up BWI's market share with their technologically-superior and safer PFA catheters that don't cause strokes.

 

[anonymous]

Not anymore. CSS was basically BWI. BWI is falling faster than a dress on prom night with their Varipulse catheter that causes strokes, and both Boston Scientific and Medtronic are gobbling up BWI's market share with their technologically-superior and safer PFA catheters that don't cause strokes.

Blue Prom Dress? Don’t let it get “stained”

 

[Senior V.P.]

Why will they? CSS is fastest growing business in MedTech.

Here is why.:

1. JJMT/CSS California and EMEA high labor & benefit costs, highest in the world. Those ping pong tables and two year paternity leave policies cost lots of money. Google model. Also relatively lower employee productivity. Here in EMEA we take off three month summer “holiday” and six socializing coffee breaks per day.

2. JJMT overall very high labor costs when compared to JJIM. If you have seen a JJIM plant, very few hourly people unlike thousands in JJMT plants. JJMT trying to address by eliminating US union shops with new mfg. sites in low cost countries but those efforts are short-term fixes only.

3. Zero and slow innovation in JJMT. JJIM is on fire with innovation. No comparison, not even close.

4. JJIM has much higher market share generally than JJMT other than BioSurgery. Stelara & Remicade for example but that is a double edged sword when they go off patent after 17 years.

5. JJMT has historically had significant liability and legal costs such as pelvic mesh, hips, stents, etc,

6. Major headwind for JJIM last four years had been government involvement in drug pricing policies but that may go away now.

 

[anonymous]

Will the new WW President clean up the dead weight at Cerenovus? With the company on the block not really sure why anyone would want to join that team right now.

 

[anonymous]

Will the new WW President clean up the dead weight at Cerenovus? With the company on the block not really sure why anyone would want to join that team right now.

Commercial is very confident of Cerenovus gaining more share due to innovation focused NPIs planned this year.

 

[anonymous]

Commercial is very confident of Cerenovus gaining more share due to innovation focused NPIs planned this year.

Put me down for skeptical. The track record of NPI is poor. Last to market and botched launches seem to be the norm there. Maybe that was Celine and Mark’s fault?

 

[anonymous]

Commercial is very confident of Cerenovus gaining more share due to innovation focused NPIs planned this year.

Not a chance. CNV is a giant cluster fvck inside a dumspter fire. Exemplary of the mess the that J&J has become. Innovation means more packaging colors than your competitor.

 

[anonymous]

Not a chance. CNV is a giant cluster fvck inside a dumspter fire. Exemplary of the mess the that J&J has become. Innovation means more packaging colors than your competitor.

Why else would it be on the block to be sold? Christian is a finance guy looking to get it ready for sale.

 

[anonymous]

Why else would it be on the block to be sold? Christian is a finance guy looking to get it ready for sale.

This is correct. Christian will clean up the books and cut the waste and help this org prepare for sell off. He and MB will do a great job.

 

[anonymous]

Why are there 3 TM openings at the same time in NYC, Philly and D.C.? Is there a mass exodus?